1. Home
  2. PCRX vs TRS Comparison

PCRX vs TRS Comparison

Compare PCRX & TRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • TRS
  • Stock Information
  • Founded
  • PCRX 2006
  • TRS 1986
  • Country
  • PCRX United States
  • TRS United States
  • Employees
  • PCRX N/A
  • TRS N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • TRS Industrial Specialties
  • Sector
  • PCRX Health Care
  • TRS Industrials
  • Exchange
  • PCRX Nasdaq
  • TRS Nasdaq
  • Market Cap
  • PCRX 1.2B
  • TRS 1.0B
  • IPO Year
  • PCRX 2011
  • TRS 2007
  • Fundamental
  • Price
  • PCRX $24.10
  • TRS $27.18
  • Analyst Decision
  • PCRX Buy
  • TRS Strong Buy
  • Analyst Count
  • PCRX 9
  • TRS 1
  • Target Price
  • PCRX $29.89
  • TRS $40.00
  • AVG Volume (30 Days)
  • PCRX 546.7K
  • TRS 341.3K
  • Earning Date
  • PCRX 07-29-2025
  • TRS 07-29-2025
  • Dividend Yield
  • PCRX N/A
  • TRS 0.59%
  • EPS Growth
  • PCRX N/A
  • TRS N/A
  • EPS
  • PCRX N/A
  • TRS 0.77
  • Revenue
  • PCRX $702,772,000.00
  • TRS $939,580,000.00
  • Revenue This Year
  • PCRX $7.54
  • TRS $6.37
  • Revenue Next Year
  • PCRX $10.78
  • TRS $5.49
  • P/E Ratio
  • PCRX N/A
  • TRS $35.34
  • Revenue Growth
  • PCRX 3.08
  • TRS 3.80
  • 52 Week Low
  • PCRX $11.16
  • TRS $19.33
  • 52 Week High
  • PCRX $29.61
  • TRS $28.51
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 36.99
  • TRS 61.50
  • Support Level
  • PCRX $23.99
  • TRS $26.16
  • Resistance Level
  • PCRX $24.90
  • TRS $27.45
  • Average True Range (ATR)
  • PCRX 0.88
  • TRS 0.75
  • MACD
  • PCRX -0.21
  • TRS -0.05
  • Stochastic Oscillator
  • PCRX 11.61
  • TRS 70.18

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About TRS TriMas Corporation

TriMas Corp designs, develops and manufactures a diverse set of products primarily for the consumer products, aerospace & defense, and industrial markets . The company operates through three segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The aerospace segment supplies blind bolts, fasteners, rivets, and other products for the aerospace industry. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners.

Share on Social Networks: